menu
    • menu
    [{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ Rayner Surgical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner Surgical Group Limited"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic-alpha-1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Nemera","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Nemera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nemera \/ Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"15","companyTruncated":"Nemera \/ Ache Laboratorios Farmaceuticos SA"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Evolution Research Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Evolution Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Evolution Research Group"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Inapplicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Undisclosed"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ University of Rochester Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ University of Rochester Medical Center"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Nuance Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Neumentum","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nuance Pharma \/ Neumentum","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Neumentum"}]

    Find Clinical Drug Pipeline Developments & Deals for Dolac

    Menu

    Dolac

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Dr. Reddy's Laboratories

    India
    CPhI Japan
    Booth #5N-12
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Lead Product(s) : Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets ...

    Details : Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug (“NSAID”) indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as con...

    Product Name : Ketorolac-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 24, 2022

    Lead Product(s) : Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    Dr Reddy Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Concentric Analgesics Data Shows Durable Pain Relief and Earlier Opioid Cessation

    Details : CA-008 (vocacapsaicin) a water-soluble prodrug of capsaicin, rapidly releases capsaicin at surgical site triggering the activation of the TRPV1 receptor on pain-specific nerves, producing analgesia.

    Product Name : CA-008

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 08, 2024

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Omeros

    U.S.A arrow
    AAN
    Not Confirmed

    Omeros

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

    Therapeutic Area : Ophthalmology

    Study Phase : Approved FDF

    Sponsor : Rayner

    Deal Size : $1,326.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

    Details : Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.

    Product Name : Omidria

    Product Type : Other Small Molecule

    Upfront Cash : $126.0 million

    June 02, 2023

    Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved FDF

    Sponsor : Rayner

    Deal Size : $1,326.0 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Nuance Pharma

    China arrow
    AAN
    Not Confirmed

    Nuance Pharma

    China arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Neumentum

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Nuance Pharma Announces the Completion of Dosing for All NTM-001 Phase 1 Clinical Study Participants in HKU Cl...

    Details : Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.

    Product Name : NTM-001

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 26, 2022

    Lead Product(s) : Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Neumentum

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Omeros

    U.S.A arrow
    AAN
    Not Confirmed

    Omeros

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : DRI Healthcare Trust

    Deal Size : $188.4 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust

    Details : Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.

    Product Name : Omidria

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    March 10, 2022

    Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : DRI Healthcare Trust

    Deal Size : $188.4 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Evolution Research Group

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain The...

    Details : The company has entered into a formal agreement with Evolution Research Group (ERG), a leading postsurgical pain clinical research site network in the U.S., to conduct its registration trials with CA-008 (vocacapsaicin).

    Product Name : CA-008

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 02, 2022

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Evolution Research Group

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : University of Rochester Medical Center

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain The...

    Details : URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin’s benefit to patient recovery and rehabilitation.

    Product Name : CA-008

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 02, 2022

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : University of Rochester Medical Center

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed

    Concentric Analgesics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Undisclosed

    Deal Size : $20.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it P...

    Details : Concentric intends to use the proceeds from the financing to further fund Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for postsurgical pain.

    Product Name : CA-008

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 26, 2022

    Lead Product(s) : Vocacapsaicin,Paracetamol,Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Undisclosed

    Deal Size : $20.0 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Omeros

    U.S.A arrow
    AAN
    Not Confirmed

    Omeros

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

    Therapeutic Area : Ophthalmology

    Study Phase : Approved FDF

    Sponsor : Rayner

    Deal Size : $1,326.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

    Details : As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.

    Product Name : Omidria

    Product Type : Other Small Molecule

    Upfront Cash : $126.0 million

    December 23, 2021

    Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved FDF

    Sponsor : Rayner

    Deal Size : $1,326.0 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Nemera

    France arrow
    AAN
    Not Confirmed

    Nemera

    France arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ketorolac Trometamol

    Therapeutic Area : Neurology

    Study Phase : Approved FDF

    Sponsor : Ache Laboratorios Farmaceuticos SA

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Nemera’s Preservative-Free Multi-Dose Eyedropper Approved in Brazil for Aché’s NSAID’s and Dry Eye Form...

    Details : Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually aft...

    Product Name : Clilon

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 05, 2021

    Lead Product(s) : Ketorolac Trometamol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Sponsor : Ache Laboratorios Farmaceuticos SA

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth